NCT00563784View on ClinicalTrials.gov

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions
Non-Small Cell Lung CancerLung Cancer
Interventions
DRUG

Erlotinib

150 mg by mouth daily for 7 Weeks

DRUG

Carboplatin

2 AUC by vein weekly for 7 Weeks

DRUG

Paclitaxel

45 mg/m\^2 by vein weekly for 7 Weeks

RADIATION

Radiation Therapy

63 GY/35 fractions for 7 weeks (+/- 5 days)

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

United States Department of Defense

FED

lead

M.D. Anderson Cancer Center

OTHER